Vinod  Labhasetwar,  Ph.D.

Vinod Labhasetwar, Ph.D.


Lerner Research Institute, 9500 Euclid Avenue, Cleveland, Ohio 44195
Location: ND2-100
Phone: (216) 445-9364
Fax: (216) 444-9198

Labhasetwar Laboratory


Our laboratory's research focus is on exploring unique attributes of nanotechnology to find effective therapy for diseases that are difficult to treat, or for which there is no treatment. We investigate, design, develop, and evaluate potential new "nanomedicines," with the ultimate objective of translating our research from bench to bedside. In our current research projects, we aim to: (a) understand the role of epigenetic changes in tumor drug resistance and metastasis and create nanotherapeutics to treat both primary and metastatic tumors; (b) explore effective therapies for stroke, particularly methods of preventing reperfusion injury and facilitating neurological repair mechanisms; (c) investigate novel neuroprotective and regenerative therapies for spinal cord injury and blast-associated traumatic brain injury; (d) develop a balloon-based delivery system for treating peripheral artery disease; and (e) find a treatment that can delay photoreceptor degeneration in retinitis pigmentosa. In our pursuits, we are innovative and active in developing new intellectual property, as well as in the patenting, licensing, and commercialization of our technologies to ultimately benefit patients. Our research is funded primarily by the National Institutes of Health and the Department of Defense.

In other words ...

Our research focus is to explore the use of nanotechnology (such as tiny "nanoparticles" that can find their way into specific cells or tissues) to treat various diseases, particularly cancer, stroke, and spinal cord and cardiovascular conditions. To fight cancer, we are developing therapies to treat both original tumors and those that have spread elsewhere and are not responding to standard treatment.

Vijayaraghavalu S, Gao Y, Rahman MT, Rozica R, Sharifi N, Midura RJ, Labhasetwar V. Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. Biomaterials, 227, 2020, 119558.

Picked as the Editor’s Choice Article in Science Translational Medicine 27 Nov 2019:
Vol. 11, Issue 520, eaaz9759 DOI: 10.1126/

Andrabi SS, Yang J, Gao Y, Kuang Y, Labhasetwar V. Nanoparticles with antioxidant enzymes protect injured spinal cord from neuronal cell apoptosis by attenuating mitochondrial dysfunction. J Control Release, 317, 2020, 300-311.

Lu S, Morris VB, Labhasetwar V. Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells. J Pharmacol Exp Ther. 370(3), 2019, 902-910.

Vijayaraghavalu S, Labhasetwar V. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells. Drug Deliv Transl Res. 8, 2018 1289-1299. doi: 10.1007/s13346-018-0556-y.

For complete list of publications, Google Scholar

US Patent Patent Title Issue Date First-Named Inventor
10,517,934 Compositions and methods for the treatment of photoaging and other conditions 12/31/2019 Vinod Labhasetwar
10,226,885 Nanogel-mediated drug delivery 2/19/2019 Vinod Labhasetwar
10,016,488 Nitric oxide synthase nanoparticles for treatment of vascular disease 7/10/2018 Vinod Labhasetwar

02/11/2020 |  

NIH Awards $2M to Evaluate t-PA Nanoconjugate for Stroke Treatment

Vinod Labhasetwar, PhD, Staff and Endowed Chair in Nanomedicine, Department of Biomedical Engineering, received a 5-year, $2 million grant from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, to investigate a novel stroke therapy that uses a tissue plasminogen activator (tPA) conjugated to nanoparticles. Dr. Labhasetwar is collaborating with M. Shazam Hussain, MD, Director, Cerebrovascular Center at Cleveland Clinic, on this project.

01/13/2020 |  

Cancer Treatment with Nanoparticles Changes Course of Bone Metastasis

A novel combination therapy that includes sustained-release biodegradable nanoparticles loaded with the cancer drug docetaxel (TXT) is highly effective in halting further progression of cancer bone metastasis in a preclinical model, according to a study published in the journal Biomaterials. These findings offer a promising new approach for treating bone metastasis.